Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens
- PMID: 35727163
- DOI: 10.1097/QAD.0000000000003289
Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens
Abstract
Objective: The primary objective was to explore weight and BMI changes in people with HIV (PWH) undergoing integrase strand transfer inhibitors (INSTI)-based regimens (vs. non-INSTI) in a large cohort and in the subsets of individuals without diabetes and insulin resistance (IR) at the time of switch to INSTI. The secondary objective was to identify risk factors for IR and cut-off of weight or BMI increase associated with IR in PWH switching to INSTI.
Design: A longitudinal matched-cohort study including PWH attending Modena HIV Metabolic Clinic, Italy.
Methods: PWH were divided into two groups: non-INSTI and INSTI-switch. The effect of switching to INSTI on weight and BMI change was tested through a linear mixed model. A mediation analysis explored the mediation effect of weight and BMI change in the association between the switch to INSTI and IR.
Results: We analyzed 2437 PWH (1025 INSTI-switch, 1412 non-INSTI), in 54 826 weight assessments. Trends for weight increase were significantly higher in early-INSTI-switch (vs. early-non-INSTI), but no difference was observed in the late period after the switch. In the subset of 634 PWH without IR, switching to INSTI (vs. non-INSTI) was associated with a lower risk of IR (hazard ratio = 0.70, 95% confidence interval: 0.51, 0.98). A weight increase by 1% reduced the total protective effect of INSTI by 21.1% over 1 year of follow-up, which identifies a 5% weight increase as a clinically meaningful weight gain definition.
Conclusion: A cut-off of 5% weight gain from the time of INSTI-switch is associated with IR, which may be a clinically meaningful endpoint that could be used in clinical and research settings.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.J Int AIDS Soc. 2020 Apr;23(4):e25484. doi: 10.1002/jia2.25484. J Int AIDS Soc. 2020. PMID: 32294337 Free PMC article.
-
Association between switching to integrase strand transfer inhibitors and incident diabetes in people with HIV.AIDS. 2024 Sep 1;38(11):1696-1702. doi: 10.1097/QAD.0000000000003954. Epub 2024 Jun 11. AIDS. 2024. PMID: 38864578
-
Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants.PLoS One. 2021 May 5;16(5):e0251205. doi: 10.1371/journal.pone.0251205. eCollection 2021. PLoS One. 2021. PMID: 33951089 Free PMC article.
-
Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism.Curr HIV/AIDS Rep. 2024 Dec;21(6):293-308. doi: 10.1007/s11904-024-00708-x. Epub 2024 Aug 29. Curr HIV/AIDS Rep. 2024. PMID: 39207722 Free PMC article. Review.
-
Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.HIV Med. 2016 Oct;17 Suppl 5:3-16. doi: 10.1111/hiv.12440. HIV Med. 2016. PMID: 27714978 Review.
Cited by
-
Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study.Viruses. 2024 Apr 15;16(4):613. doi: 10.3390/v16040613. Viruses. 2024. PMID: 38675955 Free PMC article.
-
Weight Gain in Overweight and Obese People with HIV-The OBHIV Cohort.J Clin Med. 2024 Feb 21;13(5):1211. doi: 10.3390/jcm13051211. J Clin Med. 2024. PMID: 38592054 Free PMC article.
-
The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV.AIDS. 2024 Jul 15;38(9):1323-1332. doi: 10.1097/QAD.0000000000003903. Epub 2024 Apr 18. AIDS. 2024. PMID: 38597416 Free PMC article.
-
Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda.BMC Infect Dis. 2023 Apr 14;23(1):230. doi: 10.1186/s12879-023-08174-3. BMC Infect Dis. 2023. PMID: 37060030 Free PMC article.
-
Weight Gain and Antiretroviral Therapy.Infect Dis Clin North Am. 2024 Sep;38(3):499-515. doi: 10.1016/j.idc.2024.04.005. Epub 2024 Jun 12. Infect Dis Clin North Am. 2024. PMID: 38871568 Review.
References
-
- Freitas P, Carvalho D, Santos AC, Matos MJ, Madureira AJ, Marques R, et al. Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on antiretroviral therapy . J Endocrinol Invest Italy 2012; 35:964–970.
-
- Nduka CU, Uthman OA, Kimani PK, Stranges S. Body fat changes in people living with HIV on antiretroviral therapy . AIDS Rev 2016; 18:198–211.
-
- Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV . N Engl J Med 2019; 381:803–815.
-
- Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D: A: D study . HIV Med 2016; 17:255–268.
-
- Palella F, Hou Q, Li JMJ, Carlson JK, Durham M, Ward D, et al. Weight gain among PWH who switch to ART-containing InSTIs or TAF. CROI 2021, March 6-10, 2021, Abstr No. 504. Available at: https://www.croiconference.org/wp-content/uploads/sites/2/resources/2021... [Accessed 6 April 2021].
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical